Faculty

Alison C. Roxby

Adjunct Associate Professor, Epidemiology
Associate Professor, Medicine - Allergy and Infectious Dis.
Associate Professor, Global Health
Medical Director, Roosevelt Infectious Disease Clinic, Medicine - Allergy and Infectious Dis.

206-685-5699

Education

MD University of North Carolina (Chapel Hill), 2003
MSc Public Health in Developing Countries, London School of Hygiene & Tropical Medicine (UK), 2002
BA French, International Studies, University of North Carolina (Chapel Hill), 1996

Contact

206-685-5699

Box 359909
University of Washington
Seattle, WA

Bio

Dr. Roxby's research goals are to improve maternal health, promote family planning, and reduce perinatal and adolescent acquisition of human immunodeficiency virus (HIV). She completed a K23 career development award studying immune activation during pregnancy and contraception in HIV-infected Kenyan women, and currently holds two National Institutes of Health grants studying contraception and the vaginal microbiome, and sexually transmitted infection acquisition in Kenyan adolescent girls. She teaches in the Department of Global Health. Dr. Roxby sees adult HIV and PrEP patients at Madison Clinic and at Roosevelt Virology Clinic, where she serves as Clinic Director.

Research Areas

Research Interests

HIV and Women; family planning and HIV risk; genital immunology; prevention of mother to child transmission of HIV

Recent Publications (PubMed)

Pregnancy and contraceptive use among participants of childbearing potential in the HVTN 705 HIV vaccine trial in Southern Africa.
(2025)
Front Reprod Health 7(): 1565933
Mda P, Mngadi K, Zhang B, Burnham R, Juraska M, Hyrien O, Garrett N, Dubula T, Toni S, Joseph S, Kotze P, Buchbinder S, Takalani A, Tomaka F, Luedtke A, Willems W, Swann E, Hutter J, Gelderblom H, McElrath MJ, Lavreys L, Stranix-Chibanda L, Roxby AC, Bekker LG, Gray GE
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines.
(2025)
Front Immunol 16(): 1557009
Ackerley CG, Edupuganti S, Yu C, Roxby AC, Seaton KE, Bekker LG, Allen M, DeRosa SC, Yates NL, Heptinstall J, Mkhize NN, Malahleha M, Mngadi K, Daniels B, Innes C, Furch BD, Koutsoukos M, Ferrari G, Morris L, Montefiori DC, McElrath MJ, Tomaras GD, Laher F, Moodie Z
Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085.
(2025 Apr 1)
J Acquir Immune Defic Syndr 98(4): 340-345
Theodore DA, Neradilek M, Gillespie K, Edupuganti S, Hinojosa JC, Lama JR, De La Grecca R, Wu YH, Davis A, Mangini D, Andrew P, Marovich MA, Zwerski S, Broder G, Andrasik MP, Castor D, Roxby AC, Cohen M, Huang Y, Karuna ST, Sobieszczyk ME
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV.
(2025 Feb 19)
BMC Immunol 26(1): 8
Chawana TD, Walsh SR, Stranix-Chibanda L, Chirenje ZM, Yu C, Zhang L, Seaton KE, Heptinstall J, Zhang L, Paez CA, Gamble T, Karuna ST, Andrew P, Hanscom B, Sobieszczyk ME, Edupuganti S, Gay CL, Mannheimer SB, Hurt CB, Stephenson KE, Polakowski LL, Spiegel H, Yacovone M, Regenold S, Yen C, Baumblatt JA, Gama L, Barouch DH, Piwowar-Manning E, Koup RA, Tomaras GD, Hyrien O, Roxby AC, Huang Y, HVTN 127/HPTN 087, HVTN 130/HPTN 089 and HVTN 136/HPTN 092 Study Teams
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.
(2024)
PLOS Glob Public Health 4(9): e0003319
Naicker V, Laher F, Bekker LG, Seaton KE, Allen M, De Rosa S, Yates NL, Mkhize NN, Saunders K, Heptinstall J, Malahleha M, Mngadi K, Daniels B, Innes C, Yu C, Modise T, Bekker V, Grunenberg N, Furch B, Miner MD, Phogat S, Diazgranados CA, Gurunathan S, Koutsoukos M, Van Der Meeren O, Roxby AC, Ferrari G, Morris L, Montefiori D, McElrath MJ, Tomaras GD, Moodie Z
Show complete publication list